Design and Rationale for ComParison Between TicagreLor and ClopidogrEl on MIcrocirculation in Patients with Acute COronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial

Overview

Journal J Cardiovasc Transl Res

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2018 Jan 19

PMID 29344840

Citations 4

Authors

Kyungil Park

Young-Rak Cho

Jong-Sung Park

Tae-Ho Park

Moo-Hyun Kim

Young-Dae Kim

Affiliations

Soon will be listed here.

Abstract

It has been previously demonstrated that ticagrelor can reduce mortality compared to clopidogrel in acute coronary syndrome (ACS) patients. However, the mechanism for this mortality reduction remains uncertain. The objective of the present study is to assess the impact of chronic ticagrelor treatment on microvascular circulation. A total of 120 participants aged 20-85 years with clinical diagnosis of ACS will be randomized in a 1:1 fashion to the following two groups: ticagrelor 90 mg twice daily; clopidogrel 75 mg once daily. To evaluate the status of microcirculation, the primary end point is coronary microvascular dysfunction measured using an index of microcirculatory resistance (IMR) at 6 months after receiving the study agent. The purpose of this trial is to investigate whether ticagrelor, beyond its antiplatelet efficacy, could improve coronary microcirculation more effectively than clopidogrel for patients with ACS.

Citing Articles

Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome.

Moon H, Jo Y, Kim S, Jo S, Park K Health Qual Life Outcomes. 2021; 19(1):242.

PMID: 34656119 PMC: 8520288. DOI: 10.1186/s12955-021-01875-w.

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI.

Guo Y, Zhao Z, Li S, Chen L Sci Rep. 2021; 11(1):17144.

PMID: 34433885 PMC: 8387390. DOI: 10.1038/s41598-021-96606-y.

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.

Zheng W, Li Y, Tian J, Li L, Xie L, Mao Q Biomed Res Int. 2019; 2019:3170957.

PMID: 31016189 PMC: 6448338. DOI: 10.1155/2019/3170957.

Ticagrelor and aspirin increased vein graft patency after coronary artery bypass grafting but does it matter?.

Zlotnik D, Cholley B, Godier A J Thorac Dis. 2018; 10(Suppl 26):S3263-S3265.

PMID: 30370133 PMC: 6186583. DOI: 10.21037/jtd.2018.08.96.

References

Levine G, Bates E, Blankenship J, Bailey S, Bittl J, Cercek B . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular.... Circulation. 2011; 124(23):2574-609. DOI: 10.1161/CIR.0b013e31823a5596. View

Hicks K, Tcheng J, Bozkurt B, Chaitman B, Cutlip D, Farb A . 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop.... J Am Coll Cardiol. 2015; 66(4):403-69. DOI: 10.1016/j.jacc.2014.12.018. View

Ng M, Yeung A, Fearon W . Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006; 113(17):2054-61. DOI: 10.1161/CIRCULATIONAHA.105.603522. View

Varenhorst C, Alstrom U, Scirica B, Hogue C, Asenblad N, Storey R . Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012; 60(17):1623-30. DOI: 10.1016/j.jacc.2012.07.021. View

Fearon W, Balsam L, Farouque H, Caffarelli A, Robbins R, Fitzgerald P . Novel index for invasively assessing the coronary microcirculation. Circulation. 2003; 107(25):3129-32. DOI: 10.1161/01.CIR.0000080700.98607.D1. View

Fredholm B, IJzerman A, Jacobson K, Linden J, Muller C . International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev. 2011; 63(1):1-34. PMC: 3061413. DOI: 10.1124/pr.110.003285. View

Shah R, Rashid A, Hwang I, Fan T, Khouzam R, Reed G . Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. Am J Cardiol. 2017; 119(11):1723-1728. DOI: 10.1016/j.amjcard.2017.03.011. View

Park S, Lee M, Baek Y, Kwon S, Shin S, Woo S . Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). EuroIntervention. 2016; 12(8):e964-e971. DOI: 10.4244/EIJV12I8A159. View

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View

10.

Shryock J, Belardinelli L . Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol. 1997; 79(12A):2-10. DOI: 10.1016/s0002-9149(97)00256-7. View

11.

Headrick J, Ashton K, RoseMeyer R, Peart J . Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol Ther. 2013; 140(1):92-111. DOI: 10.1016/j.pharmthera.2013.06.002. View

12.

Sezer M, Umman B, Okcular I, Nisanci Y, Umman S . Relationship between microvascular resistance and perfusion in patients with reperfused acute myocardial infarction. J Interv Cardiol. 2007; 20(5):340-50. DOI: 10.1111/j.1540-8183.2007.00274.x. View

13.

Gibson C, Morrow D, Murphy S, Palabrica T, Jennings L, Stone P . A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006; 47(12):2364-73. DOI: 10.1016/j.jacc.2005.12.077. View

14.

Cavallari I, Nusca A, Ricottini E, Di Sciascio G . Prognostic role of platelet reactivity in patients with acute coronary syndromes. Cardiol Rev. 2014; 22(6):313-8. DOI: 10.1097/CRD.0000000000000034. View

15.

Vilahur G, Gutierrez M, Casani L, Varela L, Capdevila A, Pons-Llado G . Protective Effects of Ticagrelor on Myocardial Injury After Infarction. Circulation. 2016; 134(22):1708-1719. DOI: 10.1161/CIRCULATIONAHA.116.024014. View

16.

McGeoch R, Watkins S, Berry C, Steedman T, Davie A, Byrne J . The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2010; 3(7):715-22. DOI: 10.1016/j.jcin.2010.04.009. View

17.

Rao A, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber T . Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11(1):1-11. DOI: 10.1016/0735-1097(88)90158-1. View

18.

Kunadian V, James S, Wojdyla D, Zorkun C, Wu J, Storey R . Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013; 6(7):671-83. DOI: 10.1016/j.jcin.2013.03.014. View

19.

Serebruany V . Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?. Am Heart J. 2010; 161(1):1-4. DOI: 10.1016/j.ahj.2010.09.017. View

20.

Fearon W, Low A, Yong A, McGeoch R, Berry C, Shah M . Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation. 2013; 127(24):2436-41. PMC: 5429864. DOI: 10.1161/CIRCULATIONAHA.112.000298. View